Imugene tweeted about Dr Bilal Shah delivering an encore presentation at the iwCAR-T 2024 meeting in Florida, on 'Updates for Allo CAR-T PBCAR0191: Bijal Shah'.
What is also interesting is that 2 members of our Scientific Advosry Board also presented at this conference. So Imugene definitely has some firepower in the CAR-T space.
Under CAR-T advances in Lung cancer:
Tumor immune modulation in solid tumor CAR T-cell therapy: Prasad Adusumilli.
Under Genitourinary cancers.
Advancing engineered T-cell therapies for solid tumors: Saul Priceman
GLTAH
IMU Price at posting:
7.7¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)